The European healthcare technology and medical technology sectors have entered a period of definitive industrial maturity as of early 2026. This era is characterised by a fundamental shift away from the liquidity-fueled exuberance of the early 2020s toward a disciplined, metrics-driven environment where strategic value is defined by clinical utility, regulatory resilience, and technological defensibility. Within this landscape, the role of financial advisory has undergone a r

The global financial landscape in the first week of February 2026 was defined by a profound and systemic recalibration of risk, characterised by a transition from liquidity-driven expansion to a regime of rigid valuation discipline. Within this broader market turbulence, the healthcare technology and digital health sectors experienced heightened volatility, acting as a microcosm of the tension between long-term innovation and short-term capital constraints. While the sell-off